Spots Global Cancer Trial Database for A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Official Title: A Phase II, Single-arm, Open-label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy
Study ID: NCT00509769
Conditions
Interventions
Study Description
Brief Summary: This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Little Rock Hem Onc Assoc, Little Rock, Arkansas, United States
Rocky Mountain Cancer Center, Denver, Colorado, United States
Washington Cancer Institute, Washington, District of Columbia, United States
Lynn Cancer Institute - West, Boca Raton, Florida, United States
Florida Cancer Care, Davie, Florida, United States
Mayo Clinic, Jacksonville, Florida, United States
Hem/Onc Assoc - Treasure Coast, Port St Lucie, Florida, United States
Gulfcoast Oncology Associates, Saint Petersburg, Florida, United States
Bay Area Oncology, Tampa, Florida, United States
Northwest Georgia Onc Ctrs PC, Marietta, Georgia, United States
John McClean, M.D. - Private P, Galesburg, Illinois, United States
Cedar Valley Med Specialists, Waterloo, Iowa, United States
Kentuckiana Cancer Institute, Louisville, Kentucky, United States
Minnesota Oncology Hematology,, Minneapolis, Minnesota, United States
Missouri Cancer Associates, Columbia, Missouri, United States
Kansas City Cancer Center, LLC, Lee's Summit, Missouri, United States
St. Louis Cancer & Breast Inst, Saint Louis, Missouri, United States
St. Barnabas Health Care Sys, Livingston, New Jersey, United States
New York Oncology Hematology, Albany, New York, United States
Eastchester Center/Cancer Care, Bronx, New York, United States
Carolinas Hem-Oncology Assoc, Charlotte, North Carolina, United States
Raleigh Hemotology & Oncology, Raleigh, North Carolina, United States
Midwestern Regional Med Center, Eugene, Oregon, United States
Texas Oncology Cancer Center, Austin, Texas, United States
Texas Oncology, P.A., Bedford, Texas, United States
Cancer Specialists of South Te, Corpus Christi, Texas, United States
US Oncology Research, Inc., Dallas, Texas, United States
USO, Dallas, Texas, United States
Texas Oncology, P.A., Dallas, Texas, United States
Sammons Cancer Center, Dallas, Texas, United States
El Paso Cancer Treatment Ctr, El Paso, Texas, United States
Texas Oncology PA, Fort Worth, Texas, United States
Texas Oncology, P.A., Houston, Texas, United States
US Oncology, Midland, Texas, United States
USO - Tyler Cancer Ctr, Tyler, Texas, United States
Waco Cancer Care & Research Ce, Waco, Texas, United States
Northern Utah Associates, Ogden, Utah, United States
Fairfax N Virginia Hem/Onc PC, Fairfax, Virginia, United States
Northwest Medical Specialties, Tacoma, Washington, United States
Northwest Cancer Specialists, Vancouver, Washington, United States
Contact Details
Name: Scott Holden, M.D.
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
